• Home

  • Documents

  • Home - ClinicalTrials.gov...Protocol Date: December 16, 2015 Statistical Analysis Plan (SAP) Date:...
64

Home - ClinicalTrials.gov...Protocol Date: December 16, 2015 Statistical Analysis Plan (SAP) Date: March 3, 2017 1.0 TITLE PAGE : Allergan study sc1401 A Randomized, Multicenter, Double-blind,

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

  •          

                  

  •    

       

       

       

       

                   

       

       

             

          

          

                

          

       

                      

       

       

       

     

     

  •    

           

               

           

          

       

       

       

         

     


Official Protocol Title - ClinicalTrials.gov · 2019. 1. 18. · Official Protocol Title: NCT number: NCT02738879 Document Date: 14-Jul-2016 A Phase III, Multicenter, Randomized,

Official Protocol Title - ClinicalTrials.gov · 2019. 1. 18. · Official Protocol Title: NCT number: NCT02738879 Document Date: 14-Jul-2016 A Phase III, Multicenter, Randomized,

Documents
$PHQGPHQW - ClinicalTrials.gov

$PHQGPHQW - ClinicalTrials.gov

Documents
BGB-3111-206 (NCT03206970) - ClinicalTrials.gov · 2018. 9. 6. · BGB-3111-206 (NCT03206970)A Single-Arm, Open-Label, Multicenter Phas e 2 Study to Evaluate Efficacy and Safety of

BGB-3111-206 (NCT03206970) - ClinicalTrials.gov · 2018. 9. 6. · BGB-3111-206 (NCT03206970)A Single-Arm, Open-Label, Multicenter Phas e 2 Study to Evaluate Efficacy and Safety of

Documents
Study Protocol A multicenter ... - ClinicalTrials.gov

Study Protocol A multicenter ... - ClinicalTrials.gov

Documents
TM - Allergan

TM - Allergan

Documents
NCT03054870 - clinicaltrials.gov

NCT03054870 - clinicaltrials.gov

Documents
Allergan, Inc. $2,500 Deductible Prescription Drug Plan...2016/01/01  · ALLERGAN, INC. $2,500 DEDUCTIBLE PRESCRIPTION DRUG PLAN SECTION 1 - WELCOME SECTION 1 - WELCOME Allergan,

Allergan, Inc. $2,500 Deductible Prescription Drug Plan...2016/01/01  · ALLERGAN, INC. $2,500 DEDUCTIBLE PRESCRIPTION DRUG PLAN SECTION 1 - WELCOME SECTION 1 - WELCOME Allergan,

Documents
Study ID UBR MD A Phase Double Blind, Placebo Single Attack Study · 2019. 1. 9. · Allergan Confidential SAP UBR-MD-02 1 1. Title Page STATISTICAL ANALYSIS PLAN A Phase 3, Multicenter,

Study ID UBR MD A Phase Double Blind, Placebo Single Attack Study · 2019. 1. 9. · Allergan Confidential SAP UBR-MD-02 1 1. Title Page STATISTICAL ANALYSIS PLAN A Phase 3, Multicenter,

Documents
Study ID CMO US GI - ClinicalTrials.gov · 2019-01-22 · NCT02959983 Study ID: CMO‐US‐GI‐0429 Title: A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo‐Controlled,

Study ID CMO US GI - ClinicalTrials.gov · 2019-01-22 · NCT02959983 Study ID: CMO‐US‐GI‐0429 Title: A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo‐Controlled,

Documents
Allergan v. Sandoz

Allergan v. Sandoz

Documents
NAXIVA - ClinicalTrials.gov

NAXIVA - ClinicalTrials.gov

Documents
This is Allergan Brochure_072016

This is Allergan Brochure_072016

Documents
PROTOCOL SYNOPSIS - ClinicalTrials.gov · This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs

PROTOCOL SYNOPSIS - ClinicalTrials.gov · This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs

Documents
Glaucoma Pocket Practice Guide - Allergan · Provided compliments of Allergan, makers of: Glaucoma Pocket Practice Guide 2nd Edition For the Ophthalmic Technician ©2010 Allergan,

Glaucoma Pocket Practice Guide - Allergan · Provided compliments of Allergan, makers of: Glaucoma Pocket Practice Guide 2nd Edition For the Ophthalmic Technician ©2010 Allergan,

Documents
2016 ALLERGAN SUSTAINABILITY PERFORMANCE REPORT...2011–2015 Allergan Strategic Performance Goals & Results 7 Allergan’s 2020 Goals 7 ... Allergan plc is a bold, global pharmaceutical

2016 ALLERGAN SUSTAINABILITY PERFORMANCE REPORT...2011–2015 Allergan Strategic Performance Goals & Results 7 Allergan’s 2020 Goals 7 ... Allergan plc is a bold, global pharmaceutical

Documents
GILEAU - ClinicalTrials.gov

GILEAU - ClinicalTrials.gov

Documents
Instructions for Use Rx Only Gelesis, Inc. · 2019-04-09 · The Gelesis Loss Of Weight (GLOW) trial (ClinicalTrials.gov, NCT02307279) was a multicenter, randomized, double-blind,

Instructions for Use Rx Only Gelesis, Inc. · 2019-04-09 · The Gelesis Loss Of Weight (GLOW) trial (ClinicalTrials.gov, NCT02307279) was a multicenter, randomized, double-blind,

Documents
Titlpage - ClinicalTrials.gov

Titlpage - ClinicalTrials.gov

Documents
Allergan Biostatistics Analysis Plan Clinical Study Report€¦ · Allergan Biostatistics Analysis Plan – Clinical Study Report Study ID: CMO-US-GI-0429 Study Title: A Phase 4 Multicenter,

Allergan Biostatistics Analysis Plan Clinical Study Report€¦ · Allergan Biostatistics Analysis Plan – Clinical Study Report Study ID: CMO-US-GI-0429 Study Title: A Phase 4 Multicenter,

Documents
CENA713DJP02 protocol ver3 - ClinicalTrials.gov · 2019. 5. 6. · [Exelon/Rivastigmine] Clinical Trial Protocol [CENA713DJP02] NCT02703636 [A 24-week, open-label, multicenter study

CENA713DJP02 protocol ver3 - ClinicalTrials.gov · 2019. 5. 6. · [Exelon/Rivastigmine] Clinical Trial Protocol [CENA713DJP02] NCT02703636 [A 24-week, open-label, multicenter study

Documents
BGB-3111-206 (NCT03206970) - ClinicalTrials.gov · 2020. 4. 1. · BGB-3111-206 (NCT03206970)A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of

BGB-3111-206 (NCT03206970) - ClinicalTrials.gov · 2020. 4. 1. · BGB-3111-206 (NCT03206970)A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of

Documents
USC-ALLERGAN FELLOWSHIP PROGRAM...USC-Allergan Fellowship Program 2016 - 2017 Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and

USC-ALLERGAN FELLOWSHIP PROGRAM...USC-Allergan Fellowship Program 2016 - 2017 Allergan plc (NYSE:AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and

Documents
Allergan FCA Complaint

Allergan FCA Complaint

Documents
Allergan 2010 Annual Report

Allergan 2010 Annual Report

Documents
USC-ALLERGAN FELLOWSHIP PROGRAMpharmacyschool.usc.edu/files/2016/08/USC-Allergan-Fellowship...USC-Allergan Fellowship Program 2017 - 2018 Allergan plc (NYSE: AGN), headquartered in

USC-ALLERGAN FELLOWSHIP PROGRAMpharmacyschool.usc.edu/files/2016/08/USC-Allergan-Fellowship...USC-Allergan Fellowship Program 2017 - 2018 Allergan plc (NYSE: AGN), headquartered in

Documents
TRICOLOR - clinicaltrials.gov

TRICOLOR - clinicaltrials.gov

Documents
VIVID - clinicaltrials.gov

VIVID - clinicaltrials.gov

Documents
EWOLUTION - ClinicalTrials.gov

EWOLUTION - ClinicalTrials.gov

Documents
ABCD - ClinicalTrials.gov · Secondary objective:to describe the profile of uncontrolled patients Study design: This observational multicenter and cross-sectional study will be conducted

ABCD - ClinicalTrials.gov · Secondary objective:to describe the profile of uncontrolled patients Study design: This observational multicenter and cross-sectional study will be conducted

Documents
A Multicenter, Open-label, Single-arm, Study of ...clinicaltrials.gov/ProvidedDocs/71/NCT02669771/Prot_000.pdfSponsor: Astellas Scientific and Medical Affairs (ASMA) 1 Astellas Way

A Multicenter, Open-label, Single-arm, Study of ...clinicaltrials.gov/ProvidedDocs/71/NCT02669771/Prot_000.pdfSponsor: Astellas Scientific and Medical Affairs (ASMA) 1 Astellas Way

Documents